Clinical-stage immuno-oncology company TapImmune, Inc. (NASDAQ: TPIV) today announced plans to participate in two upcoming investor and industry conferences. First, Dr. Glynn Wilson, chairman and CEO of TapImmune, will be offering an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York City. Wilson’s presentation is scheduled for 10:35 am ET on Tuesday, March 28, 2017. The full presentation will be webcast live and archived for future viewing at http://tapimmune.com/events. Second, Dr. John Bonfiglio, president and chief operating officer of TapImmune, will be providing an overview of the company’s unique approach during a presentation titled ‘Synthesis, Purification and Formulation of a New T Cell Vaccine Using 5 Novel Proteins’ at the S2 Oligonucleotide & Peptide Therapeutics Boston Conference on Wednesday, March 29, 2017, at 1:30 pm ET.
To view the full press release, visit http://nnw.fm/ZX9vS
About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman’s cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the company’s website at www.tapimmune.com for more details.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
